The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Protection of adjuvant trastuzumab in sites of early relapses.
M. Campiglio
No relevant relationships to disclose
E. Tagliabue
No relevant relationships to disclose
A. Balsari
No relevant relationships to disclose
R. Bufalino
No relevant relationships to disclose
E. Ferri
No relevant relationships to disclose
L. Gianni
Consultant or Advisory Role - Genentech; GlaxoSmithKline; Pfizer; Roche; Wyeth
S. Ménard
No relevant relationships to disclose